Steven A. Kaplan, MD

"In the current environment of coronavirus disease 2019 (COVID-19), it has become obvious that it won’t be business as usual when the economy restarts and social distancing restrictions are relaxed," write Steven A. Kaplan, MD, and Alexis E. Te, MD.

"Through all this, I have never been more optimistic that together we will be stronger both in the urologic community and the medical community as a whole," writes Steven A. Kaplan, MD.

"We have entered a renaissance in the care for patients with benign prostatic hyperplasia-related lower urinary tract symptoms," writes Steven A. Kaplan, MD.

"When analyzing efficacy of minimally invasive/surgical therapies for lower urinary tract symptoms secondary to BPH, we appropriately focus on subjective criteria and objective criteria. While we discuss retreatment rates, we don’t measure failure of therapies by how many men restart LUTS/BPH medications," writes Steven A. Kaplan, MD.

In this interview, Steven A. Kaplan, MD, highlights the key updates to the 2018 guideline that differentiates it from the AUA’s 2010 guideline on this topic.

Most urologists agree that surgical removal of the enlarged portion of the prostate is the most effective and durable way to manage lower urinary tract symptoms in men secondary to BPH. Where it gets interesting is deriving urologic consensus on the best way to achieve that goal.